For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
A phase II study of tazemetostat (EPZ-6438) (IND#138671) in recurrent or persistent endometrioid or clear cell carcinoma of the ovary, and recurrent or persistent endometrioid endometrial adenocarcinoma
To find out if this approach is better or worse than the usual approach for your ovarian or endometrial cancer.
DiagnosisPathologically proven diagnosis of recurrent or persistent ovarian endometrioid or clear cell carcinoma, OR recurrent or persistent endometrioid endometrial adenocarcinoma.
Must have completed prior therapy anywhere from 14 days to 6 weeks before registration depending on which therapy regimen was assigned.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Tazemetostat 800 mg (4 tablets by mouth two times a day) until disease progression or unacceptable toxicity.
- Patients must keep a pill diary.
Follow ups occur every 3 months for 2 years and then every 6 months for 3 years (5 years total).
For more information, visit ClinicalTrials.gov